WO2018226058A3 - 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 - Google Patents
콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 Download PDFInfo
- Publication number
- WO2018226058A3 WO2018226058A3 PCT/KR2018/006506 KR2018006506W WO2018226058A3 WO 2018226058 A3 WO2018226058 A3 WO 2018226058A3 KR 2018006506 W KR2018006506 W KR 2018006506W WO 2018226058 A3 WO2018226058 A3 WO 2018226058A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pedf
- preventing
- pharmaceutical composition
- active ingredients
- pigment epithelium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 콜라겐 및 34-mer 색소 상피성 인자(PEDF) 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물에 관한 것으로, 보다 상세하게는 콜라겐 타입 Ⅰ과 34-mer PEDF 펩타이드 병용 투여를 통하여 PEDF의 짧은 항혈관신생 활성주기에 증가시키고, PEDF의 투여 용량 범위를 확장시킬 수 있으므로, 종래의 PEDF 잦은 주입에 따른 불편함과 그에 따른 부작용 문제를 해결할 수 있으며, 다양한 혈관신생질환 치료제로 적용이 가능하다.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880037986.6A CN110869045B (zh) | 2017-06-08 | 2018-06-08 | 包含i型胶原及色素上皮衍生因子肽作为有效成分的预防或治疗新生血管性疾病的药物组合物 |
EP18814409.1A EP3636275B1 (en) | 2017-06-08 | 2018-06-08 | Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients |
US16/619,947 US11197918B2 (en) | 2017-06-08 | 2018-06-08 | Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0071521 | 2017-06-08 | ||
KR1020170071521A KR101906494B1 (ko) | 2017-06-08 | 2017-06-08 | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2018226058A2 WO2018226058A2 (ko) | 2018-12-13 |
WO2018226058A3 true WO2018226058A3 (ko) | 2019-04-11 |
WO2018226058A9 WO2018226058A9 (ko) | 2019-05-31 |
Family
ID=64566002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/006506 WO2018226058A2 (ko) | 2017-06-08 | 2018-06-08 | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11197918B2 (ko) |
EP (1) | EP3636275B1 (ko) |
KR (1) | KR101906494B1 (ko) |
CN (1) | CN110869045B (ko) |
WO (1) | WO2018226058A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020213993A1 (ko) * | 2019-04-18 | 2020-10-22 | 한양대학교 에리카산학협력단 | 신혈관 생성 억제용 융합 폴리펩타이드, 다가성 신혈관 생성 억제용 펩타이드를 가진 융합단백질 나노케이지 및 이의 테라노스틱스 용도 |
KR102412681B1 (ko) * | 2019-04-18 | 2022-06-27 | 한양대학교 에리카산학협력단 | 다중 자극 반응성 블록 코폴리펩타이드 기반 약물전달체 |
KR102413729B1 (ko) * | 2019-04-18 | 2022-06-29 | 한양대학교 에리카산학협력단 | 신혈관 생성 억제용 융합 폴리펩타이드, 다가성 신혈관 생성 억제용 펩타이드를 가진 융합단백질 나노케이지 및 이의 테라노스틱스 용도 |
WO2024144099A1 (ko) * | 2022-12-27 | 2024-07-04 | 주식회사 넥스세라 | 안구 질환 치료를 위한 효율적인 약물 전달 플랫폼 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014786A2 (en) * | 2014-07-24 | 2016-01-28 | Yale University | Pigment epithelium-derived factor (pedf) and peptide derivatives thereof for use in osteoblast differentiation and bone growth |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004027027A2 (en) * | 2002-09-18 | 2004-04-01 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
JP2005336159A (ja) * | 2004-04-28 | 2005-12-08 | Univ Kurume | Nadphオキシダーゼ活性を抑制する色素上皮由来因子の新規治療用途 |
WO2006046584A1 (ja) | 2004-10-26 | 2006-05-04 | Santen Pharmaceutical Co., Ltd. | 視細胞障害治療剤 |
KR20170123502A (ko) | 2016-04-29 | 2017-11-08 | 부경대학교 산학협력단 | 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 |
-
2017
- 2017-06-08 KR KR1020170071521A patent/KR101906494B1/ko active
-
2018
- 2018-06-08 WO PCT/KR2018/006506 patent/WO2018226058A2/ko unknown
- 2018-06-08 EP EP18814409.1A patent/EP3636275B1/en active Active
- 2018-06-08 US US16/619,947 patent/US11197918B2/en active Active
- 2018-06-08 CN CN201880037986.6A patent/CN110869045B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014786A2 (en) * | 2014-07-24 | 2016-01-28 | Yale University | Pigment epithelium-derived factor (pedf) and peptide derivatives thereof for use in osteoblast differentiation and bone growth |
Non-Patent Citations (4)
Title |
---|
BELKACEMI, LOUIZA: "Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 35, 2016, pages 1 - 14, XP055590136 * |
FILLEUR, STEPHANIE: "Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer", CANCER RESEARCH, vol. 65, no. 12, 2005, pages 5144 - 5152, XP002651215, DOI: doi:10.1158/0008-5472.can-04-3744 * |
HE, XUEMIN: "PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases", CLINICAL SCIENCE, vol. 128, no. 11, 2015, pages 805 - 823, XP055590150 * |
HOSOMICHI, JUN: "Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epithelium-derived factor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 335, no. 3, 2005, pages 756 - 761, XP005035570 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018226058A2 (ko) | 2018-12-13 |
CN110869045A (zh) | 2020-03-06 |
CN110869045B (zh) | 2023-10-20 |
US11197918B2 (en) | 2021-12-14 |
EP3636275B1 (en) | 2023-08-09 |
US20210077599A1 (en) | 2021-03-18 |
EP3636275A4 (en) | 2021-03-10 |
EP3636275A2 (en) | 2020-04-15 |
KR101906494B1 (ko) | 2018-12-05 |
WO2018226058A9 (ko) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018226058A3 (ko) | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
PH12017502092A1 (en) | Topical pharmaceutical compositions | |
JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
WO2017155232A3 (ko) | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
UA117506C2 (uk) | Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти | |
MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
NO20075945L (no) | Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav | |
BR112015027992A2 (pt) | uso de ácido petroselínico para combater desordens estéticas da figura do corpo | |
MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
MX2021006654A (es) | Uso de extracto de cocculus hirsutus para tratar dengue. | |
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
MX2023003401A (es) | Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo. | |
NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
MX2021008687A (es) | Una composicion para el tratamiento de la periodontitis y la regeneracion de la papila interdental. | |
WO2019017676A3 (ko) | 에틸바닐린을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
WO2019066548A3 (ko) | 심부전의 예방 또는 치료용 약학적 조성물 | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18814409 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018814409 Country of ref document: EP Effective date: 20200108 |